If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think we actually predicted here that Gilead might try combining Remdesivir with interferon beta. Actually I mean I know I said precisely that, but I think someone else pointed out Gilead's nebuliser move first. Why they would want to use the injected form - especially while moving remdesivir to nebulised form - is beyond me. Maybe there's a patent in the way?
Given all we know, it would extremely surprising if the injected form worked better than the nebulised form. We know it means a much higher dose to get it where it needs to go, and we know that means unwanted side effects.
Looking at how long it took SNG to come up with the formulation-nebuliser combo, I'd expect that it's not an easy thing to do. Which suggests that it will take time/money for rivals to develop alternatives. If you were a pharma, would you invest millions into reinventing the wheel for a chance to shoot for a higher margin, or just pay off SNG for using their tech and make money from day 1?
Let’s hope it turns out a masterpiece....
Reads and sounds good to me / patent on formulation and delivery system - others may produce interferon beta and nebuliser but haven’t managed to put the two together unlike Synairgen....GLA
I’m no valuation expert but Venrock wouldn’t be investing unless they saw some decent upside from the current share price. Exactly what that figure is is the hard bit to estimate. My guess is they can see significant upside or they wouldn’t be investing at all.....topping up suggests they would like a meaningful stake in the company to make their research/resource commitment worthwhile.
Spinnaker,
This makes sense to me, if I recall some twenty five years ago we applied for patents in the U.S and six territories in Europe and could have still filed a PCT, however that
process does become very expensive when you come to eventually choose which countries you are going to continue your patent application in, we in our case just kept to what we thought would be our main markets. However with Synairgen resources I think they have covered all bases just in case, it’s looking really really good from an IP prospective. I’m very happy with the outcome from the research from others on this board including yourself, gbk47, SGD7 and johnht
Thanks gkb47 jint etc. I opened the link thanks. No I hand't seen it before. I see this is from 2011 application. I don't know whether this covers the SNG001 formulation and or method of application as it presently is. The document excludes the USA and I'm not that clear on the 2 digit country references.
Thanks to jint for confirming the PCT allows time to make applications for patents in other countries.
Another previous post here had a link to what I thought was a more recent patent for USA and Europe so I have no idea why they are different. I don't think we can do much other than leave it to the Board and I would expect given their history they will be trying to cover all bases.
Very encouraged that the SP has been relatively stable awaiting the next news and I am still confident as I was when my initial buy in price of 70p dropped to 35p. I did sell a few shares but now topped up since the rise.
PCT covers all territories covered until decisions are taken whether or not to proceed in individual territories GLA
Apologies, didn’t see the post PCT in place, all very very good news GLA
spinnaker, SGD7 and gkb7 some really great points and thanks for sharing.
@jint, there is nothing specifically different that I am aware of between tech vs pharma. However, I've had a number of instances of patents being sufficiently different from previous iterations for a new application to be made and accepted. But as it stands there is still a lot of time available to Synairgen.
Just checking, having taken out a patent over 20 years ago (now run out). The time frames for other patent applications in other territories were very strict ie from time of initial filing with the U.K. patent office. Obviously mine was non Pharma related, so the question is are Pharma applications allowed a different time frame. GLA
2.20 Just paid.......
Thanks gkb47...Had not seen that...they are certainly on top of things..
Would not expect anything else..
Great find..Thanks!!
Thanks spinnaker, very interesting!
Here's a link :
https://www.wipo.int/treaties/en/registration/pct/summary_pct.html
Thanks for your input on this johnht. I was amazed to see that China is a member of the Patent Co-operation Treaty (PCT)!
Google search 'WIPO-Administered Treaties; Patent Cooperation Treaty (PCT) The Patent Cooperation Treaty makes it possible to seek patent protection for an invention simultaneously in each of a large number of countries by filing an "international" patent application. Such an application may be filed by anyone who is a national or resident of a PCT .'
Am I right in assuming that no other person or company in a country that was a member of the PCT could apply for a patent on anything patented by another company in another member country? If so this in itself would give a good measure of protection of the IP but there again, without protection of a large local Pharma there would be little likelihood of enforcement!
I realise that EU and USA together is a large market but the rest of the world is far larger and protection of IP internationally would give scope for a much larger potential market anfd therefore value for SNG.
Once emergency approval is made, the partnership will make the capacity to supply everywhere. The IP is pretty water tight for the vast majority of territories - as I've mentioned earlier.
Doubt they would have the capacity to supply more than Europe and usa
"The thing is that SNG do not have a worldwide patent"
You cannot obtain a universal “world patent” or “international patent”. There should be relevant information on auth. codes; PCT (administered by WIPO), EP, GB and US amongst others, and also Notice of Allocation.
They are well covered where it matters.
Grayking.
Although the trial was phase 2, I agree with your main point and I brought up the same point a few days ago. The only response I recall was Europe and US is big enough. The thing is that SNG do not have a worldwide patent and I would expect this would need to be applied for to have any chance of preventing knock-off reverse engineered copies of solution and nebuliser within a few weeks or months of release. As you suggest large partners or licensees would be needed in eastern regions to fund and protect IP in those areas. It may be of course that the BoD are either dealing with this now or taking the attitude that there won't be big money to be made generally outside Europe and the US since a lot of the therapy would have to be at close to break-even or even loss making to countries like India and Pakistan. There may be money to be made in other places like the Arab states and China, even Russia, however, as you say not without an agreement with major Pharmas with the clout and connections. I presume patents would have to applied for as soon as possible but I am no expert in this field and other members may be able to throw some light on the legal ramifications and likely difficulties .
Having said this for Phase 3 trials I am sure the favourite will be the US.
WRONG.. the recent tests wers stage 2 tests..
SYN clearly need a large take up from the Stage 2 target population to confirm if not better its Stage 1 trial results. And that requires a continuing increase in serious covid cases. By now I would have expected they are working with hospitals across the globe. Question then is how many will then copy and be blowed to the legal consequences in favour of their populations health and fast profits by back street manufacturers/labs. A legal link with large International pharmas with large legal department will help mitigate this.